tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Acrivon Therapeutics price target lowered to $8 from $9 at Oppenheimer

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is on track for the second half of 2025.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1